CoronaCentral

  • Dashboard

  • Trending

  • Epidemiology
    Forecasting & Modelling
    Infection Reports
    Transmission
    Contact Tracing
    Prevalence
    Prevention
    Surveillance
  • Clinical
    Clinical Reports
    Risk Factors
    Long Haul
    Pediatrics
    Medical Specialties
    Recommendations
    Imaging
    Diagnostics
    Healthcare Workers
  • Biology
    Molecular Biology
    Immunology
    Model Systems & Tools
    Non-human
  • Treatment
    Therapeutics
    Drug Targets
    Vaccines
    Clinical Trials
    Medical Devices
  • Psychology
  • Policy
    Health Policy
    Communication
    Inequality
    Education
  • Other Articles
    Reviews
    Meta-analysis
    Comments & Editorials
    CDC Weekly Reports
    Book Chapters
    News
    Non-medical
    Retractions
    Misinformation

  • Mentions
    Drugs
    Genes or Proteins
    Genetic Variation
    Locations
    Medical Specialties
    Prevention Methods
    Risk Factors
    Species
    Symptoms
    Test Types
    Transmission Types
    Vaccine Types
    Viral Lineages

  • FAQs
  • Feedback

Immunology

Share
Research studying the interactions of the virus and the immune system
Published and Preprint Papers
Filter
Title
Altmetric
Vaccinated and unvaccinated individuals have similar viral loads in communities with a high prevalence of the SARS-CoV-2 delta variant

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.

The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.

SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern.

Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines.

Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection.

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19.

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.

Project funded by the Chan Zuckerberg Biohub and NLM grant LM05652